Bcl-xL
Bcl-xL, encoded by BCL2L1, is a major anti-apoptotic member of the BCL-2 family that regulates mitochondrial apoptosis through interactions with pro-apoptotic proteins and preservation of mitochondrial integrity[1][2]. Mechanistically, Bcl-xL suppresses mitochondrial outer membrane permeabilization, limits BAX/BAK activation, and modulates cellular bioenergetics, calcium signaling, and autophagy, linking survival pathways with metabolic adaptation under cellular stress[1][3]. Beyond canonical apoptosis control, Bcl-xL interacts with Beclin-1 and intracellular calcium regulators, including IP3 receptors and VDAC1, thereby influencing autophagy, endoplasmic reticulum-mitochondrial communication, and stress responses[1][4]. In disease models, elevated Bcl-xL expression promotes tumor cell survival, therapeutic resistance, angiogenesis, and metastatic progression across hematologic malignancies and solid tumors, including melanoma and breast cancer[1][5]. Compared with related BCL2L1 splice isoforms, Bcl-xL functions predominantly as a pro-survival protein, whereas the alternatively spliced Bcl-xS isoform exhibits pro-apoptotic activity, highlighting the biological significance of isoform-specific regulation in apoptosis research[2][6]. For experimental applications, Bcl-xL is a validated target of BH3 mimetics and other apoptosis-directed strategies, and its inhibition is widely used to investigate mitochondrial apoptotic priming, drug resistance mechanisms, and cancer cell dependency on anti-apoptotic signaling networks[1][7].
References:
- [1]. Silva JPN, et al. BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting. Int J Mol Sci. 2026;27(2):1123.
- [2]. Warren CFA, et al. BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis. 2019 Feb 21;10(3):177. [Content Brief]
- [3]. Li M, et al. Bcl-XL: A multifunctional anti-apoptotic protein. Pharmacol Res. 2020;151:104547.
- [4]. Bcl-xL gene information from NCBI.
- [5]. Kim TJ, et al. Risk of Second Primary Malignancies among Patients with Early Gastric Cancer Exposed to Recurrent Computed Tomography Scans. Cancers (Basel). 2021 Mar 7;13(5):1144. [Content Brief]
- [6]. Chen W, et al. Alternative splicing of BCL-X and implications for treating hematological malignancies. Oncol Lett. 2021;22(4):670. [Content Brief]
- [7]. Campbell KJ, et al. Targeting BCL-2 regulated apoptosis in cancer. Open Biol. 2018;8(5):180002. [Content Brief]
-
Bcl-xL Related Products (123)
Related Products (123)
-
Antibodies (1)
-
XZ338
0 ImagesCat. No.: HY-172798Purity: 98.17%XZ338 is a highly potent and selective BCL-XL PROTAC degrader derived from A-1331852 (HY-19741), with a DC50 of 0.43 nM in MOLT‑4 cells. XZ338 induces the formation of a ternary complex with BCL-XL and VHL E3 ligase, mediates target protein degradation via the ubiquitin-proteasome system, and exhibits significantly weaker degradation activity in platelets than in tumor cells. XZ338 possesses anti-cancer activity. XZ338 can be used in the research of T-cell acute lymphoblastic leukemia (T-ALL).
-
Alisol A 24-acetate
0 ImagesSynonyms: Alisol A 24-monoacetate; Alisol A monoacetateAlisol A 24-acetate (Alisol A monoacetate) is an orally active derivative of protostane-type tetracyclic triterpenoid. Alisol A 24-acetate upregulates the expression of adiponectin, AMPKα, CPT1, and ACOX1; downregulates the expression of SREBP-1c, ACC, FAS, Bcl-2, Bcl-xl, PPAR-γ, perilipin A, and NFATc1; inhibits the activity of PI3K/Akt/mTOR and HMGR; and activates the PKA and ERK signaling pathways. Alisol A 24-acetate regulates cell apoptosis (apoptosis), autophagy (Autophagy, hepatic lipid accumulation, inflammatory response, neuroprotection, MRSA membrane integrity, and osteoclast differentiation. Alisol A 24-acetate can be used in research related to non-alcoholic fatty liver disease, nephrotoxicity, obesity, global cerebral ischemia-reperfusion injury, bacterial infection, and osteoporosis.
-
Navitoclax (Standard)
0 ImagesSynonyms: ABT-263 (Standard)Navitoclax (Standard) (ABT-263 (Standard)) is the analytical standard of Navitoclax (HY-10087). This product is intended for research and analytical applications. Navitoclax (ABT-263 ) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a Ki value of <1 nM for each target. Navitoclax triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax alleviates fibrosis and induces thrombocytopenia. Navitoclax exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases.
-
Mcl-1 inhibitor 6
0 ImagesMcl-1 inhibitor 6 is an orally active, selective myeloid cell leukemia 1 (Mcl-1) protein inhibitor with a Kd of 0.23 nM and a Ki of 0.02 μM. Mcl-1 inhibitor 6 possesses superior selectivity over other Bcl-2 family members (Bcl-2, Bcl2A1, Bcl-xL, and Bcl-w, Kd>10 μM). Mcl-1 inhibitor 6 is a potent antitumor agent.
-
BCL-XL-IN-3
0 ImagesCat. No.: HY-170406CAS No.: 1949840-87-2BCL-XL-IN-3 is a cell-impermeable BCL-XL inhibitor with a Ki of 16 pM. BCL-XL-IN-3 disrupts the critical hydrogen bond network via methylation of the nitrogen atom on the P2-binding amide bond, resulting in complete loss of cellular activity against BCL-XL. BCL-XL-IN-3 can be used in non-small cell lung cancer and cancer-related research.
-
Desmorpholinyl navitoclax-NH-Me
0 ImagesSynonyms: Desmorpholinyl ABT-263-NH-MeDesmorpholinyl navitoclax-NH-Me (Desmorpholinyl ABT-263-NH-Me) is an N-methylamino-substituted derivative of Navitoclax (HY-10087) and a BCL-XL-targeting PROTAC precursor. Desmorpholinyl navitoclax-NH-Me is used for the synthesis of BCL-XL-targeting PROTACs and related research.
-
Navitoclax-d8
0 ImagesNavitoclax-d8 is the d8-labeled Navitoclax (HY-10087). Navitoclax (ABT-263 ) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a Ki value of <1 nM for each target. Navitoclax triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax alleviates fibrosis and induces thrombocytopenia. Navitoclax exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases.
-
Sorafenib-13C,d3
0 ImagesSynonyms: Bay 43-9006-13C,d3Sorafenib-13C,d3 (Bay 43-9006-13C,d3) is the 13C, deuterated-labeled Sorafenib (HY-10201). Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
-
Haplophytin-A
0 ImagesCat. No.: HY-N17612CAS No.: 366477-44-3
-
Navitoclax dihydrochloride
0 ImagesSynonyms: ABT-263 dihydrochlorideNavitoclax dihydrochloride (ABT-263 dihydrochloride) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a Ki value of <1 nM for each target. Navitoclax dihydrochloride triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax dihydrochloride alleviates fibrosis and induces thrombocytopenia. Navitoclax dihydrochloride exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax dihydrochloride can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases.
-
Apogossypolone
0 ImagesSynonyms: ApoG2Apogossypolone (ApoG2) is an orally active Bcl-2 family proteins inhibitor with Ki values of 35, 25 and 660 nM for Bcl-2, Mcl-1 and Bcl-XL, respectively. Apogossypolone shows antitumor activities, induces cell apoptosis and autophagy. Apogossypolone also has antifungal activity.
-
PZ703b TFA
0 ImagesCat. No.: HY-115718APZ703b TFA is a Bcl-xl PROTAC degradation agent that induces apoptosis and inhibits cancer cell proliferation for bladder cancer research.
-
Chelerythrine
0 ImagesCat. No.: HY-N2359CAS No.: 34316-15-9Chelerythrine is an alkaloid, acts as a potent and selective Ca2+/phospholopid-dependent PKC antagonist, with an IC50 of 0.7 μM. Chelerythrine inhibits the BclXL-Bak BH3 peptide binding with IC50 of 1.5 μM. Chelerythrine triggers Apoptosis and Autophagy. Chelerythrine has antitumor, antidiabetic and anti-inflammatory activity. Chelerythrine shows antibacterial activities against Gram-positive bacteria, Staphylococcus aureus (SA), MRSA.
-
Procyanidin B2-3'-O-gallate
0 ImagesCat. No.: HY-N16483CAS No.: 109280-47-9Procyanidin B2-3'-O-gallate is a mono-gallate ester that can be found in grape seed extract. Procyanidin B2-3'-O-gallate induces cleavage of caspase-9, caspase-3, and PARP, reduces levels of Bcl-2, Bcl-Xl, and androgen receptor and induces apoptosis. Procyanidin B2-3'-O-gallate can be used for the research of prostate cancer.
-
WEHI-539
0 ImagesCat. No.: HY-15607CAS No.: 1431866-33-9WEHI-539 is a selective inhibitor of Bcl-XL with an IC50 of 1.1 nM.
